Trial Profile
A Multicenter Phase II Trial to Evaluate the Efficacy and Safety of Pembrolizumab and Gemcitabine in Patients With HER2-negative Advanced Breast Cancer (ABC) "PANGEA-Breast"
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 12 Jan 2023
Price :
$35
*
At a glance
- Drugs Gemcitabine (Primary) ; Pembrolizumab (Primary)
- Indications Advanced breast cancer
- Focus Adverse reactions; Therapeutic Use
- Acronyms PANGEA; PANGEA-Breast
- 03 Dec 2022 Primary endpoint has not been met. (Objective Response Rate (ORR), as per Results published in the BMC Cancer
- 03 Dec 2022 Results published in the BMC Cancer
- 19 Mar 2022 Status changed from active, no longer recruiting to completed.